Person · CIK 1800670
Barbara Weber
Director at Parabilis Medicines and Tango Therapeutics
Earlier: Revolution Medicines and Opy Acquisition Corp. I
Sold on Form 4$2.4M
Noticed on Form 144$837K
Bought on Form 4$0
Companies4
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Parabilis Medicines PBLS | Stock Option (Right to Buy) exercise $20.00, expires Jun 8, 2036, into Common Stock | Directly | 20,215 | Jun 9, 2026 · Filing · EDGAR |
| Tango Therapeutics TNGX | Common Stock | Directly | 1,629,254 | Feb 3, 2026 · Filing · EDGAR |
| Tango Therapeutics TNGX | Stock Option (Right to Buy) exercise $11.94, expires Feb 2, 2036, into Common Stock | Directly | 222,132 | Feb 2, 2026 · Filing · EDGAR |
| Revolution Medicines | Common Stock | Directly | 13,065 | Oct 8, 2024 · Filing · EDGAR |
| Revolution Medicines | Stock Option (Right to Buy) exercise $37.54, expires Jun 19, 2034, into Common Stock | Directly | 15,955 | Jun 20, 2024 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) |
|---|---|---|
| Q1 2026 | $374K | — |
| Q1 2025 | $58K | — |
| Q4 2024 | $250K | $246K |
| Q3 2024 | — | $81K |
| Q1 2024 | $115K | — |
| Q3 2023 | $526K | $510K |
| Q1 2021 | $492K | Not machine-readable |
| Q4 2020 | $577K | Not machine-readable |
| Q3 2020 | $56K | Not machine-readable |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Revolution Medicines · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 29, 2024 · 1 notice | ||||
| Oct 8, 2024 | 5,200 · ~$246K | Oct 8, 2024 | Sold as noticed Sold 5,200 at $48.02 on Oct 8 · $250K Form 4 | Filing · EDGAR |
| Revolution Medicines · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice | ||||
| Aug 21, 2024 | 1,808 · ~$81K | Aug 21, 2024 | Not sold within 90 days | Filing · EDGAR |
| Revolution Medicines · Morgan Stanley Smith Barney · 10b5-1 plan adopted Dec 14, 2022 · 1 notice | ||||
| Sep 1, 2023 | 15,000 · ~$510K | Sep 1, 2023 | Sold as noticed Sold 15,000 at $35.07 on Sep 1 · $526K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 16 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 333 at $12.90 on Feb 3, 2026 · $4K | Filing · EDGAR |
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 30,186 at $12.26 on Feb 3, 2026 · $370K | Filing · EDGAR |
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 9,013 at $3.16 on Feb 5, 2025 · $28K | Filing · EDGAR |
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 9,778 at $2.99 on Feb 4, 2025 · $29K | Filing · EDGAR |
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 4,457 at $12.62 on Feb 7, 2024 · $56K | Filing · EDGAR |
| — | — | — | Sold without notice Tango Therapeutics (TNGX): Sold 4,681 at $12.56 on Feb 6, 2024 · $59K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 900 at $51.86 on Feb 4, 2021 · $47K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 4,100 at $50.02 on Feb 4, 2021 · $205K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 5,336 at $45.00 on Feb 2, 2021 · $240K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 100 at $41.33 on Dec 30, 2020 · $4K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 5,236 at $40.95 on Dec 30, 2020 · $214K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 7,196 at $36.17 on Oct 5, 2020 · $260K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 804 at $36.02 on Oct 2, 2020 · $29K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 2,000 at $34.76 on Oct 1, 2020 · $70K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 333 at $28.00 on Aug 13, 2020 · $9K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Revolution Medicines: Sold 1,667 at $28.00 on Aug 12, 2020 · $47K (10b5-1 plan) | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Tango Therapeutics TNGX Director, Executive Chair · filings 2021 to 2026 · sold $547K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 3, 2026 | Open-market or private sale | −30,186 | $12.26 | $370K | 1,629,587 direct | Filing · EDGAR |
| Feb 3, 2026 | Open-market or private sale | −333 | $12.90 | $4K | 1,629,254 direct | Filing · EDGAR |
| Feb 2, 2026 | Grant or award from the company | +37,522 | 1,659,773 direct | Filing · EDGAR | ||
| Feb 2, 2026 | Grant or award from the company Stock Option (Right to Buy) | +222,132 | 222,132 direct | Filing · EDGAR | ||
| Feb 5, 2025 | Open-market or private sale | −9,013 | $3.16 | $28K | 1,622,251 direct | Filing · EDGAR |
| Feb 4, 2025 | Open-market or private sale | −9,778 | $2.99 | $29K | 1,631,264 direct | Filing · EDGAR |
| Feb 3, 2025 | Grant or award from the company | +105,875 | 1,641,042 direct | Filing · EDGAR | ||
| Feb 3, 2025 | Grant or award from the company Stock Option (Right to Buy) | +635,250 | 635,250 direct | Filing · EDGAR | ||
| Feb 7, 2024 | Open-market or private sale | −4,457 | $12.62 | $56K | 1,535,167 direct | Filing · EDGAR |
| Feb 6, 2024 | Open-market or private sale | −4,681 | $12.56 | $59K | 1,539,624 direct | Filing · EDGAR |
| Feb 1, 2024 | Grant or award from the company | +87,168 | 87,168 direct | Filing · EDGAR | ||
| Feb 1, 2024 | Grant or award from the company Stock Option (Right to Buy) | +523,012 | 523,012 direct | Filing · EDGAR | ||
| Mar 1, 2023 | Grant or award from the company | +89,545 | 1,457,137 direct | Filing · EDGAR | ||
| Mar 1, 2023 | Grant or award from the company Stock Option (Right to Buy) | +537,273 | 537,273 direct | Filing · EDGAR | ||
| Feb 1, 2022 | Grant or award from the company Stock Option (Right to Buy) | +625,000 | 625,000 direct | Filing · EDGAR | ||
| Aug 12, 2021 | Grant or award from the company Stock Option (Right to Buy) | +961,403 | 961,403 direct | Filing · EDGAR |
Revolution Medicines Director · filings 2020 to 2024 · sold $1.9M · $837K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 8, 2024 | Sale under a 10b5-1 plan | −5,200 | $48.02 | $250K | 13,065 direct | Filing · EDGAR |
| Aug 21, 2024 | Returned to the company | −1,808 | $44.83 | $81K | 18,265 direct | Filing · EDGAR |
| Jun 20, 2024 | Grant or award from the company | +4,248 | 20,073 direct | Filing · EDGAR | ||
| Jun 20, 2024 | Grant or award from the company Stock Option (Right to Buy) | +15,955 | 15,955 direct | Filing · EDGAR | ||
| Sep 1, 2023 | Option or RSU exercised or converted | +3,854 | $1.12 | $4K | 19,679 direct | Filing · EDGAR |
| Sep 1, 2023 | Option or RSU exercised or converted | +11,146 | $4.73 | $53K | 30,825 direct | Filing · EDGAR |
| Sep 1, 2023 | Sale under a 10b5-1 plan | −15,000 | $35.07 | $526K | 15,825 direct | Filing · EDGAR |
| Sep 1, 2023 | Option or RSU exercised or converted Stock Option (Right to Buy) | −3,854 | 9,635 direct | Filing · EDGAR | ||
| Sep 1, 2023 | Option or RSU exercised or converted Stock Option (Right to Buy) | −11,146 | 1,851 direct | Filing · EDGAR | ||
| Jun 8, 2023 | Grant or award from the company | +5,200 | 15,825 direct | Filing · EDGAR | ||
| Jun 8, 2023 | Grant or award from the company Stock Option (Right to Buy) | +18,400 | 18,400 direct | Filing · EDGAR | ||
| Jun 16, 2022 | Grant or award from the company | +5,200 | 10,625 direct | Filing · EDGAR | ||
| Jun 16, 2022 | Grant or award from the company Stock Option (Right to Buy) | +18,400 | 18,400 direct | Filing · EDGAR | ||
| Jun 22, 2021 | Grant or award from the company | +3,617 | 5,425 direct | Filing · EDGAR | ||
| Jun 22, 2021 | Grant or award from the company Stock Option (Right to Buy) | +12,659 | 12,659 direct | Filing · EDGAR | ||
| Feb 4, 2021 | Option or RSU exercised or converted | +5,000 | $4.73 | $24K | 6,808 direct | Filing · EDGAR |
| Feb 4, 2021 | Sale under a 10b5-1 plan | −4,100 | $50.02 | $205K | 2,708 direct | Filing · EDGAR |
| Feb 4, 2021 | Sale under a 10b5-1 plan | −900 | $51.86 | $47K | 1,808 direct | Filing · EDGAR |
| Feb 4, 2021 | Option or RSU exercised or converted Stock Option (Right to Buy) | −5,000 | 12,997 direct | Filing · EDGAR | ||
| Feb 2, 2021 | Option or RSU exercised or converted | +5,336 | $1.12 | $6K | 7,144 direct | Filing · EDGAR |
| Feb 2, 2021 | Sale under a 10b5-1 plan | −5,336 | $45.00 | $240K | 1,808 direct | Filing · EDGAR |
| Feb 2, 2021 | Option or RSU exercised or converted Stock Option (Right to Buy) | −5,336 | 13,489 direct | Filing · EDGAR | ||
| Dec 30, 2020 | Other acquisition or disposition (see the filing) Stock Option (Right to Buy) | −0 | 18,825 direct | Filing · EDGAR | ||
| Dec 30, 2020 | Option or RSU exercised or converted | +5,336 | $1.12 | $6K | 7,144 direct | Filing · EDGAR |
| Dec 30, 2020 | Sale under a 10b5-1 plan | −5,236 | $40.95 | $214K | 1,908 direct | Filing · EDGAR |
| Dec 30, 2020 | Sale under a 10b5-1 plan | −100 | $41.33 | $4K | 1,808 direct | Filing · EDGAR |
| Dec 30, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −5,336 | 13,489 direct | Filing · EDGAR | ||
| Oct 5, 2020 | Option or RSU exercised or converted | +7,196 | $1.12 | $8K | 9,004 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −7,196 | $36.17 | $260K | 1,808 direct | Filing · EDGAR |
| Oct 5, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −7,196 | 18,825 direct | Filing · EDGAR | ||
| Oct 2, 2020 | Option or RSU exercised or converted | +804 | $1.12 | $900 | 2,612 direct | Filing · EDGAR |
| Oct 2, 2020 | Sale under a 10b5-1 plan | −804 | $36.02 | $29K | 1,808 direct | Filing · EDGAR |
| Oct 2, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −804 | 26,021 direct | Filing · EDGAR | ||
| Oct 1, 2020 | Option or RSU exercised or converted | +2,000 | $1.12 | $2K | 3,808 direct | Filing · EDGAR |
| Oct 1, 2020 | Sale under a 10b5-1 plan | −2,000 | $34.76 | $70K | 1,808 direct | Filing · EDGAR |
| Oct 1, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −2,000 | 26,825 direct | Filing · EDGAR | ||
| Aug 13, 2020 | Option or RSU exercised or converted | +333 | $1.12 | $373 | 2,141 direct | Filing · EDGAR |
| Aug 13, 2020 | Sale under a 10b5-1 plan | −333 | $28.00 | $9K | 1,808 direct | Filing · EDGAR |
| Aug 13, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −333 | 28,825 direct | Filing · EDGAR | ||
| Aug 12, 2020 | Option or RSU exercised or converted | +1,667 | $1.12 | $2K | 3,475 direct | Filing · EDGAR |
| Aug 12, 2020 | Sale under a 10b5-1 plan | −1,667 | $28.00 | $47K | 1,808 direct | Filing · EDGAR |
| Aug 12, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −1,667 | 29,158 direct | Filing · EDGAR | ||
| Jun 17, 2020 | Grant or award from the company | +1,808 | 1,808 direct | Filing · EDGAR | ||
| Jun 17, 2020 | Grant or award from the company Stock Option (Right to Buy) | +6,329 | 6,329 direct | Filing · EDGAR |
Opy Acquisition Corp. I Director · filings 2021 to 2021
No transactions in the filings read; Form 144 notices are listed above.
All 31 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Jun 11, 2026 | Form 4 | Parabilis Medicines PBLS | Filing · EDGAR |
| Jun 9, 2026 | Form 3 | Parabilis Medicines PBLS | Filing · EDGAR |
| Feb 4, 2026 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Feb 6, 2025 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Feb 5, 2025 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Oct 10, 2024 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Oct 8, 2024 | Form 144 | Revolution Medicines | Filing · EDGAR |
| Aug 23, 2024 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Aug 21, 2024 | Form 144 | Revolution Medicines | Filing · EDGAR |
| Jun 28, 2024 | Form 4/A | Revolution Medicines | Filing · EDGAR |
| Jun 24, 2024 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Feb 8, 2024 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Feb 5, 2024 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Sep 6, 2023 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Sep 1, 2023 | Form 144 | Revolution Medicines | Filing · EDGAR |
| Jun 12, 2023 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Mar 2, 2023 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Jun 17, 2022 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Feb 3, 2022 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Oct 27, 2021 | Form 3 | Opy Acquisition Corp. I | Filing · EDGAR |
| Aug 16, 2021 | Form 4 | Tango Therapeutics TNGX | Filing · EDGAR |
| Aug 12, 2021 | Form 3 | Tango Therapeutics TNGX | Filing · EDGAR |
| Jun 24, 2021 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Feb 5, 2021 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Feb 3, 2021 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Jan 8, 2021 | Form 4/A | Revolution Medicines | Filing · EDGAR |
| Jan 4, 2021 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Oct 5, 2020 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Aug 14, 2020 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Jun 19, 2020 | Form 4 | Revolution Medicines | Filing · EDGAR |
| Feb 12, 2020 | Form 3 | Revolution Medicines | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.